Si-Bone Inc (SIBN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Si-Bone Inc stock (SIBN) is currently trading at $12.91. Si-Bone Inc PS ratio (Price-to-Sales) is 2.85. Analyst consensus price target for SIBN is $25.67. WallStSmart rates SIBN as Sell.
- SIBN PE ratio analysis and historical PE chart
- SIBN PS ratio (Price-to-Sales) history and trend
- SIBN intrinsic value — DCF, Graham Number, EPV models
- SIBN stock price prediction 2025 2026 2027 2028 2029 2030
- SIBN fair value vs current price
- SIBN insider transactions and insider buying
- Is SIBN undervalued or overvalued?
- Si-Bone Inc financial analysis — revenue, earnings, cash flow
- SIBN Piotroski F-Score and Altman Z-Score
- SIBN analyst price target and Smart Rating
Si-Bone Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Si-Bone Inc (SIBN) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Si-Bone Inc (SIBN) Key Strengths (1)
97.83% of shares held by major funds and institutions
Supporting Valuation Data
Si-Bone Inc (SIBN) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Premium pricing at 3.2x book value
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 2.85x sales
Solid revenue growth at 15.00% per year
Si-Bone Inc (SIBN) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (2.85), Price/Book (3.18) suggest expensive pricing. Growth concerns include Revenue Growth at 15.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -11.00%, Operating Margin at -4.37%, Profit Margin at -9.41%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -11.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 15.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SIBN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SIBN's Price-to-Sales ratio of 2.85x trades at a deep discount to its historical average of 9.49x (2th percentile). The current valuation is 86% below its historical high of 20.99x set in Apr 2021, and 2% above its historical low of 2.81x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~3.6x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Si-Bone Inc (SIBN) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Si-Bone Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 201M with 15% growth year-over-year. The company is currently unprofitable, posting a -9.4% profit margin.
Key Findings
Generating 440,000 in free cash flow and 2M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -9.4% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Si-Bone Inc.
Bottom Line
Si-Bone Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Si-Bone Inc(SIBN)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and internationally. The company is headquartered in Santa Clara, California.